The U.S. government has contracted with the Canadian firm Cangene Corp. on a $362 million agreement for a botulism treatment, the first award for that potential bioterror agent. (BioWorld Today)

The U.S. government has contracted with the Canadian firm Cangene Corp. on a $362 million agreement for a botulism treatment, the first award for that potential bioterror agent. (BioWorld Today)

The FDA approved the biosimilar product Omnitrope (somatropin [rDNA origin]), a follow-on version of a growth hormone drug, in a landmark decision that reverberated among both supporters and opponents. (BioWorld Today)

The FDA approved the biosimilar product Omnitrope (somatropin [rDNA origin]), a follow-on version of a growth hormone drug, in a landmark decision that reverberated among both supporters and opponents. (BioWorld Today)